GMAB:NSD-Genmab A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 29.32

Change

0.00 (0.00)%

Market Cap

USD 18.31B

Volume

0.76M

Avg Analyst Target

USD 38.50 (+31.31%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Genmab A/S (GMAB) Stock Analysis:
Based on the Genmab A/S stock forecasts from 10 analysts, the average analyst target price for Genmab A/S is USD 38.50 over the next 12 months. Genmab A/S’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Genmab A/S is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Genmab A/S’s stock price was USD 29.32. Genmab A/S’s stock price has changed by -4.84% over the past week, -20.22% over the past month and -20.93% over the last year.

About

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease ...Read More

Company Website : https://www.genmab.com

Address : Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Employees : 1,212

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.75

52 Week High : 49.07

Short Ratio : 2.77

52 Week Low : 27.42

Shorted Shares : 1,759,128

200 Day Moving Average : 39.23

Shorted Shares Previous Month : 1,612,212

50 Day Moving Average : 34.66

Short Percentage : 0.17%

Shares Held by Institutions : 6.21%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

 USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD63.10B 27.38 17.74
MRNA Moderna Inc

N/A

 USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.40B 3.79 1.55
RPRX Royalty Pharma plc

N/A

 USD26.93B 26.81 14.86
SGEN Seagen Inc

N/A

 USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ARGX argenx SE

N/A

 USD16.90B N/A N/A
INCY Incyte Corporation

N/A

 USD16.59B 17.54 21.87

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap
SCID Global X Scientific Beta .. 0.00 % 0.39 %

N/A

 USD3.34M
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.55 %

N/A

 USD0.09B
FINT:CA First Trust International.. 0.00 % 0.60 %

N/A

 USD8.17M
EMID:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

N/A

 USD7.79M
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

N/A

 USD0.08B
DX2I:F Xtrackers - MSCI Europe M.. 0.00 % 0.12 %

N/A

 USD0.05B
EL43:F Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

N/A

 USD0.02B
DX2I:XETRA Xtrackers - MSCI Europe M.. 0.00 % 0.12 %

N/A

 USD0.05B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

N/A

 USD0.02B
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.40 %

N/A

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.88% 79% C+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.88% 79% C+ 44% F
Trailing 12 Months  
Capital Gain -20.93% 83% B 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.93% 83% B 48% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.08% 70% C- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.08% 69% D+ 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 33.39% 83% B 48% F
Risk Adjusted Return 75.10% 97% A+ 91% A-
Market Capitalization 18.31B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.41 18% F 21% F
Price/Book Ratio 6.95 10% F 11% F
Price / Cash Flow Ratio 8.22 7% F 32% F
EV/EBITDA 4.62 21% F 70% C-
Management Effectiveness  
Return on Equity 14.56% 96% A 78% C+
Return on Invested Capital 9.89% 91% A- 74% C
Return on Assets 8.24% 96% A 89% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.77 69% D+ 54% F
Short Percent 0.17% 96% A 89% B+
Beta 0.75 76% C 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.